Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $15.46 in the prior trading day, KalVista Pharmaceuticals Inc (NASDAQ: KALV) closed at $15.66, up 1.29%. In other words, the price has increased by $1.29 from its previous closing price. On the day, 0.77 million shares were traded. KALV stock price reached its highest trading level at $15.7 during the session, while it also had its lowest trading level at $15.12.
Ratios:
Our goal is to gain a better understanding of KALV by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.21 and its Current Ratio is at 7.22. In the meantime, Its Debt-to-Equity ratio is 16.62 whereas as Long-Term Debt/Eq ratio is at 16.34.
Upgrades & Downgrades
In the most recent recommendation for this company, JMP Securities on January 31, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $19.
On January 07, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $30.
On December 18, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $22.BofA Securities initiated its Buy rating on December 18, 2024, with a $22 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 08 ’25 when Palleiko Benjamin L sold 7,294 shares for $16.51 per share. The transaction valued at 120,424 led to the insider holds 424,520 shares of the business.
Sweeny Nicole sold 3,813 shares of KALV for $51,289 on Nov 24 ’25. The Chief Commercial Officer now owns 39,728 shares after completing the transaction at $13.45 per share. On Nov 24 ’25, another insider, Piekos Brian, who serves as the Chief Financial Officer of the company, sold 4,471 shares for $13.45 each. As a result, the insider received 60,139 and left with 10,529 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KALV now has a Market Capitalization of 791554944 and an Enterprise Value of 764975936. For the stock, the TTM Price-to-Sale (P/S) ratio is 553.54 while its Price-to-Book (P/B) ratio in mrq is 46.56. Its current Enterprise Value per Revenue stands at 536.449 whereas that against EBITDA is -3.79.
Stock Price History:
The Beta on a monthly basis for KALV is -0.19, which has changed by 0.7648401 over the last 52 weeks, in comparison to a change of 0.16067612 over the same period for the S&P500. Over the past 52 weeks, KALV has reached a high of $17.30, while it has fallen to a 52-week low of $7.30. The 50-Day Moving Average of the stock is 12.61%, while the 200-Day Moving Average is calculated to be 19.66%.
Shares Statistics:
The stock has traded on average 1.30M shares per day over the past 3-months and 899350 shares per day over the last 10 days, according to various share statistics. A total of 50.54M shares are outstanding, with a floating share count of 37.84M. Insiders hold about 25.14% of the company’s shares, while institutions hold 97.14% stake in the company. Shares short for KALV as of 1765756800 were 15387745 with a Short Ratio of 11.87, compared to 1763078400 on 14454733. Therefore, it implies a Short% of Shares Outstanding of 15387745 and a Short% of Float of 34.25.
Earnings Estimates
. The current assessment of KalVista Pharmaceuticals Inc (KALV) involves the perspectives of 7 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.62, with high estimates of -$0.43 and low estimates of -$0.85.
Analysts are recommending an EPS of between -$1.65 and -$3.76 for the fiscal current year, implying an average EPS of -$3.03. EPS for the following year is -$2.09, with 8.0 analysts recommending between -$0.44 and -$2.73.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $28.33M. There is a high estimate of $39M for the next quarter, whereas the lowest estimate is $15.5M.
Based on 9 analysts’ estimates, the company’s revenue will be $120.05M in the next fiscal year. The high estimate is $242.2M and the low estimate is $33.71M.
